SAS Output

22-SEP-2017 18:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1378 375 181 77 21 2 07/08/2014 432 223
            1378 375 181 77 21 2      
 
    2 Y 17 S1400G   31 31 26 5 1 0      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        3 S1400B   53 5 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 2 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   621 309 141 61 24 9      
            1061 347 167 66 25 9      
 
    3 P 10 S1400I   8 8 2 2 1 0      
        18 S1400G   8 8 5 2 2 0      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            17 16 7 4 3 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 3 2 1 1 0 07/31/2014    
            4 3 2 1 1 0      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 29 29 28 10 3 0 03/03/2017 432 222
            29 29 28 10 3 0      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 350 112 60 24 11 1 0 12/29/2015 433 223
        2 Nivolumab   117 62 28 13 7 1      
            229 122 52 24 8 1      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 Y 1 AFATINIB + CETUXIMAB 605 70 36 25 7 3 1 05/07/2015 224 92
        2 AFATINIB   69 36 21 10 3 0      
            139 72 46 17 6 1      
 
  S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 1 Y 1 Trametinib + Docetaxel 53 37 37 17 0 0 0 10/05/2016 185 85
            37 37 17 0 0 0      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 Y 5 RT+Pac+Carbo+blinded drug 132 18 18 12 6 2 1 01/24/2013 133 54
        6 RT+Pac+Carbo+blinded drug   14 13 7 2 2 1      
            32 31 19 8 4 2      
 
    2 Y 8 Pac + Carbo + blinded drug 132 17 17 14 9 3 0 01/24/2013    
            17 17 14 9 3 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   25 13 9 3 0 0 04/01/2015   248
            25 13 9 3 0 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   365 198 101 63 18 2 12/16/2014 455 250
            365 198 101 63 18 2      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   52 2 2 2 0 0 05/14/2008 240 116
            52 2 2 2 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   5 2 2 2 1 0 02/29/2016 458 257
            5 2 2 2 1 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 4 3 2 1 0 10/20/2016 322 143
            4 4 3 2 1 0      
 
    2 E Total Registrations   4 4 3 2 1 0 10/20/2016    
            4 4 3 2 1 0      
 
  R1306-NSCLC,Adv,ALK/EGFR,TargetAgents 1 E Total Registrations   8 0 0 0 0 0 03/12/2014 162 70
            8 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   371 199 101 61 18 2 12/16/2014 455 250
            371 199 101 61 18 2      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   22 21 14 8 5 1 08/03/2016 454 244
            22 21 14 8 5 1